Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | COVID-19 prophylaxis: bolstering boosters

Samir N. Parekh • 10 Nov 2021
SITC 2021
Multiple Myeloma Antibodies CAR-T Daratumumab

Samir N. Parekh, MD, Icahn School of Medicine at Mount Sinai, New York City, NY, discusses the potential of prophylactic strategies against COVID-19 in patients with hematological malignancy, specifically commenting on how such strategies could complement booster vaccines. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Samir N. Parekh

1:03
Looking forward to ASH 2021: key updates in multiple myeloma
Samir N. Parekh • 10 Nov 2021
9:04
How does myeloma treatment choice impact COVID-19 vaccination response?
Samir N. Parekh • 10 Nov 2021
2:32
Refining the current staging system for multiple myeloma
Samir N. Parekh • 10 Nov 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals